⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for post essential thrombocythemia myelofibrosis

Every month we try and update this database with for post essential thrombocythemia myelofibrosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Study of SB939 in Subjects With MyelofibrosisNCT01200498
Myeloproliferat...
SB939
18 Years - M.D. Anderson Cancer Center
An Open Label Study of Itacitinib Administered Orally in Patients With MyelofibrosisNCT01633372
MPN (Myeloproli...
itacitinib
18 Years - Incyte Corporation
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosisNCT01433445
Idiopathic Myel...
Post Essential ...
Post Polycythem...
panobinostat
ruxolitinib
18 Years - Novartis
Study of SB939 in Subjects With MyelofibrosisNCT01200498
Myeloproliferat...
SB939
18 Years - M.D. Anderson Cancer Center
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)NCT04551066
Myelofibrosis
Primary Myelofi...
Post Essential ...
Post Polycythem...
parsaclisib
ruxolitinib
placebo
18 Years - Incyte Corporation
An Open Label Study of Itacitinib Administered Orally in Patients With MyelofibrosisNCT01633372
MPN (Myeloproli...
itacitinib
18 Years - Incyte Corporation
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)NCT04551053
Myelofibrosis
Primary Myelofi...
Post Essential ...
Post Polycythem...
parsaclisib
ruxolitinib
placebo
18 Years - Incyte Corporation
An Open Label Study of Itacitinib Administered Orally in Patients With MyelofibrosisNCT01633372
MPN (Myeloproli...
itacitinib
18 Years - Incyte Corporation
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: